{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:50:38Z","timestamp":1782143438489,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,22]]},"DOI":"10.7759\/cureus.111294","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:27:34Z","timestamp":1782142054000},"source":"Crossref","is-referenced-by-count":0,"title":["Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates"],"prefix":"10.7759","author":[{"given":"Arman M","family":"Niknafs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland F","family":"Damron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita V","family":"Baclig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"American Cancer Society: Cancer Facts & Figures 2026","author":"American Cancer Society:","year":"2026","unstructured":"American Cancer Society. : Cancer Facts & Figures 2026. American Cancer Society, Inc., Atlanta, GA; 2026. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/20...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.19524","article-title":"Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates","volume":"8","author":"Lian Y","year":"2025","unstructured":"Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates. JAMA Netw Open. 2025, 8:e2519524. 10.1001\/jamanetworkopen.2025.19524","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091780","article-title":"How immunotherapy has redefined the treatment paradigm of metastatic or locally advanced muscle-invasive urothelial bladder carcinoma","volume":"16","author":"Larroquette M","year":"2024","unstructured":"Larroquette M, Lefort F, Domblides C, H\u00e9raudet L, Robert G, Ravaud A, Gross-Goupil M. How immunotherapy has redefined the treatment paradigm of metastatic or locally advanced muscle-invasive urothelial bladder carcinoma. Cancers (Basel). 2024, 16:1780. 10.3390\/cancers16091780","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles T","year":"2024","unstructured":"Powles T, Catto JW, Galsky MD, et al.. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024, 391:1773-86. 10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.04.011","article-title":"Integrative oncology","volume":"101","author":"Lopez G","year":"2017","unstructured":"Lopez G, Mao JJ, Cohen L. Integrative oncology. Med Clin North Am. 2017, 101:977-85. 10.1016\/j.mcna.2017.04.011","journal-title":"Med Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00554","article-title":"Putting integrative oncology into practice: concepts and approaches","volume":"15","author":"Latte-Naor S","year":"2019","unstructured":"Latte-Naor S, Mao JJ. Putting integrative oncology into practice: concepts and approaches. J Oncol Pract. 2019, 15:7-14. 10.1200\/JOP.18.00554","journal-title":"J Oncol Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa M","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS. Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis. Cancers (Basel). 2025, 17:2063. 10.3390\/cancers17132063","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig TW","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, et al.. NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024. J Natl Compr Canc Netw. 2024, 22:216-25. 10.6004\/jnccn.2024.0024","journal-title":"J Natl Compr Canc Netw"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al.. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024, 390:875-88. 10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-drug conjugates for urothelial carcinoma","volume":"10","author":"Thomas J","year":"2023","unstructured":"Thomas J, Sun M, Getz T, et al.. Antibody-drug conjugates for urothelial carcinoma. Urol Oncol. 2023, 10:420-8. 10.1016\/j.urolonc.2023.06.006","journal-title":"Urol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE study","volume":"19","author":"Nizam A","year":"2025","unstructured":"Nizam A, Nguyen CB, Li J, et al.. Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE study. Cancer Med. 2025, 19:e71284. 10.1002\/cam4.71284","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot Y","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, et al.. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019, 381:338-48. 10.1056\/NEJMoa1817323","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot Y","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, et al.. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023, 389:1961-71. 10.1056\/NEJMoa2308849","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a\u00a0phase III randomized trial","volume":"36","author":"Powles T","year":"2025","unstructured":"Powles T, Tagawa S, Vulsteke C, et al.. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a\u00a0phase III randomized trial. Ann Oncol. 2025, 36:561-71. 10.1016\/j.annonc.2025.01.011","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden MS","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, et al.. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023, 389:1778-89. 10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE- 361): a randomized, open-label, phase 3 trial","volume":"22","author":"Powles T","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, et al.. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE- 361): a randomized, open-label, phase 3 trial. Lancet Oncol. 2021, 22:931-45. 10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00539-9","article-title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomized, controlled, phase 3 study","volume":"25","author":"Bamias A","year":"2024","unstructured":"Bamias A, Davis ID, Galsky MD, et al.. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomized, controlled, phase 3 study. Lancet Oncol. 2024, 25:46-61. 10.1016\/S1470-2045(23)00539-9","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomized, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles T","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, et al.. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomized, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020, 21:1574-88. 10.1016\/S1470-2045(20)30541-6","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1534735405286109","article-title":"The potential of a person-centered approach in caring for patients with cancer: a perspective from the UCLA center for East-West medicine","volume":"5","author":"Hui KK","year":"2006","unstructured":"Hui KK, Hui EK, Johnston MF. The potential of a person-centered approach in caring for patients with cancer: a perspective from the UCLA center for East-West medicine. Integr Cancer Ther. 2006, 5:56-62. 10.1177\/1534735405286109","journal-title":"Integr Cancer Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2224-5820.2013.01.14","article-title":"Using acupuncture as part of a comprehensive program in helping patients with breast cancer beyond fatigue","volume":"2","author":"Hui KK","year":"2013","unstructured":"Hui KK, Zhang L. Using acupuncture as part of a comprehensive program in helping patients with breast cancer beyond fatigue. Ann Palliat Med. 2013, 2:4-6. 10.3978\/j.issn.2224-5820.2013.01.14","journal-title":"Ann Palliat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2021.0133","article-title":"Acupuncture improves multiple treatment-related symptoms in breast cancer survivors: a systematic review and meta-analysis","volume":"27","author":"Li H","year":"2021","unstructured":"Li H, Schlaeger JM, Jang MK, et al.. Acupuncture improves multiple treatment-related symptoms in breast cancer survivors: a systematic review and meta-analysis. J Altern Complement Med. 2021, 27:1084-97. 10.1089\/acm.2021.0133","journal-title":"J Altern Complement Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.03.002","article-title":"Self-acupressure for symptom management in cancer patients: a systematic review","volume":"66","author":"Cheng HL","year":"2023","unstructured":"Cheng HL, Yeung WF, Wong HF, Lo HT, Molassiotis A. Self-acupressure for symptom management in cancer patients: a systematic review. J Pain Symptom Manage. 2023, 66:e109-28. 10.1016\/j.jpainsymman.2023.03.002","journal-title":"J Pain Symptom Manage"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.07.014","article-title":"Supportive cryotherapy: a review from head to toe","volume":"47","author":"Kadakia KC","year":"2014","unstructured":"Kadakia KC, Rozell SA, Butala AA, Loprinzi CL. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014, 47:1100-15. 10.1016\/j.jpainsymman.2013.07.014","journal-title":"J Pain Symptom Manage"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08680-3","article-title":"Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"32","author":"Tai HY","year":"2024","unstructured":"Tai HY, Lin LY, Huang TW, Gautama MS. Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer. 2024, 32:482. 10.1007\/s00520-024-08680-3","journal-title":"Support Care Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000906","article-title":"Efficacy of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer: a propensity score-matched study","volume":"85","author":"Xu M","year":"2023","unstructured":"Xu M, Wang F, Zhu X, Hao Z. Efficacy of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer: a propensity score-matched study. Ann Med Surg (Lond). 2023, 85:2695-703. 10.1097\/MS9.0000000000000906","journal-title":"Ann Med Surg (Lond)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2022-003636","article-title":"Cryotherapy for oral mucositis in cancer: review of systematic reviews and meta-analysis","volume":"13","author":"Amiri Khosroshahi R","year":"2024","unstructured":"Amiri Khosroshahi R, Talebi S, Travica N, Mohammadi H. Cryotherapy for oral mucositis in cancer: review of systematic reviews and meta-analysis. BMJ Support Palliat Care. 2024, 13:e570-7. 10.1136\/spcare-2022-003636","journal-title":"BMJ Support Palliat Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf116","article-title":"Treated well but feeling poorly: examining supportive care devices in oncology practice","volume":"30","author":"Phung QH","year":"2025","unstructured":"Phung QH, Gupta A, Rocque GB, Hussaini SM. Treated well but feeling poorly: examining supportive care devices in oncology practice. Oncologist. 2025, 30:456-70. 10.1093\/oncolo\/oyaf116","journal-title":"Oncologist"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-10058-y","article-title":"Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy","volume":"33","author":"Kaufman L","year":"2025","unstructured":"Kaufman L, Valentic L, Malley L, Icksarus C, Rose L, Dulmage B. Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy. Support Care Cancer. 2025, 33:1005. 10.1007\/s00520-025-10058-y","journal-title":"Support Care Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_67_18","article-title":"A systematic review: mindfulness intervention for cancer-related pain","volume":"6","author":"Ngamkham S","year":"2019","unstructured":"Ngamkham S, Holden JE, Smith EL. A systematic review: mindfulness intervention for cancer-related pain. Asia Pac J Oncol Nurs. 2019, 6:161-9. 10.4103\/apjon.apjon_67_18","journal-title":"Asia Pac J Oncol Nurs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2025.01.002","article-title":"Yoga-a complementary and traditional medicine for human health","volume":"23","author":"Pandey S","year":"2025","unstructured":"Pandey S, Pandey AC, Kotecha VR. Yoga-a complementary and traditional medicine for human health. J Integr Med. 2025, 23:93-105. 10.1016\/j.joim.2025.01.002","journal-title":"J Integr Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-017-0665-5","article-title":"Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis","volume":"12","author":"Wayne PM","year":"2018","unstructured":"Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, Song R. Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. J Cancer Surviv. 2018, 12:256-67. 10.1007\/s11764-017-0665-5","journal-title":"J Cancer Surviv"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/nu17213422","article-title":"Editorial: diet, nutrition, supplements, and integrative oncology in cancer care","volume":"17","author":"Frenkel M","year":"2025","unstructured":"Frenkel M, Mathis SE. Editorial: diet, nutrition, supplements, and integrative oncology in cancer care. Nutrients. 2025, 17:3422. 10.3390\/nu17213422","journal-title":"Nutrients"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00857","article-title":"Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline","volume":"41","author":"Carlson LE","year":"2023","unstructured":"Carlson LE, Ismaila N, Addington EL, et al.. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023, 41:4562-91. 10.1200\/JCO.23.00857","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01357","article-title":"Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline","volume":"40","author":"Mao JJ","year":"2022","unstructured":"Mao JJ, Ismaila N, Bao T, et al.. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2022, 40:3998-4024. 10.1200\/JCO.22.01357","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0033","article-title":"NCCN Guidelines\u00ae insights: palliative Care, version 2.2021","volume":"19","author":"Dans M","year":"2021","unstructured":"Dans M, Kutner JS, Agarwal R, et al.. NCCN Guidelines\u00ae insights: palliative Care, version 2.2021. J Natl Compr Canc Netw. 2021, 19:780-8. 10.6004\/jnccn.2021.0033","journal-title":"J Natl Compr Canc Netw"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-024-04603-1","article-title":"Acupuncture-related interventions improve chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis","volume":"24","author":"Yeh ML","year":"2024","unstructured":"Yeh ML, Liao RW, Yeh PH, Lin CJ, Wang YJ. Acupuncture-related interventions improve chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis. BMC Complement Med Ther. 2024, 24:310. 10.1186\/s12906-024-04603-1","journal-title":"BMC Complement Med Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004004","article-title":"Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study","volume":"33","author":"Ben-Arye E","year":"2023","unstructured":"Ben-Arye E, Gamus D, Samuels N, et al.. Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study. Int J Gynecol Cancer. 2023, 33:792-801. 10.1136\/ijgc-2022-004004","journal-title":"Int J Gynecol Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0681","article-title":"Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: a randomized clinical trial","volume":"3","author":"Bao T","year":"2020","unstructured":"Bao T, Patil S, Chen C, Zhi IW, Li QS, Piulson L, Mao JJ. Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: a randomized clinical trial. JAMA Netw Open. 2020, 3:e200681. 10.1001\/jamanetworkopen.2020.0681","journal-title":"JAMA Netw Open"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040250","article-title":"Efficacy of oral cryotherapy in the prevention of oral mucositis associated with cancer chemotherapy: systematic review with meta-analysis and trial sequential analysis","volume":"28","author":"Al-Rudayni AH","year":"2021","unstructured":"Al-Rudayni AH, Gopinath D, Maharajan MK, Veettil SK, Menon RK. Efficacy of oral cryotherapy in the prevention of oral mucositis associated with cancer chemotherapy: systematic review with meta-analysis and trial sequential analysis. Curr Oncol. 2021, 28:2852-67. 10.3390\/curroncol28040250","journal-title":"Curr Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2680","article-title":"Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment","volume":"2","author":"Riley P","year":"2016","unstructured":"Riley P, McCabe MG, Glenny AM. Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment. JAMA Oncol. 2016, 2:1365-6. 10.1001\/jamaoncol.2016.2680","journal-title":"JAMA Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419855134","article-title":"Influence of yoga on cancer-related fatigue and mediational relationships between changes in sleep and cancer-related fatigue: a nationwide, multicenter randomized controlled trial of yoga in cancer survivors","volume":"18","author":"Lin PJ","year":"2019","unstructured":"Lin PJ, Kleckner IR, Loh KP, et al.. Influence of yoga on cancer-related fatigue and mediational relationships between changes in sleep and cancer-related fatigue: a nationwide, multicenter randomized controlled trial of yoga in cancer survivors. Integr Cancer Ther. 2019, 18:1534735419855134. 10.1177\/1534735419855134","journal-title":"Integr Cancer Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1529","article-title":"Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer","volume":"18","author":"Lengacher CA","year":"2009","unstructured":"Lengacher CA, Johnson-Mallard V, Post-White J, et al.. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology. 2009, 18:1261-72. 10.1002\/pon.1529","journal-title":"Psychooncology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7874","article-title":"Examination of broad symptom improvement following mindfulness-based stress reduction in breast cancer survivors: a large randomized controlled trial","volume":"34","author":"Lengacher CA","year":"2016","unstructured":"Lengacher CA, Reich RR, Paterson CL, et al.. Examination of broad symptom improvement following mindfulness-based stress reduction in breast cancer survivors: a large randomized controlled trial. J Clin Oncol. 2016, 34:2827-34. 10.1200\/JCO.2015.65.7874","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel JA","year":"2022","unstructured":"Ligibel JA, Bohlke K, May AM, et al.. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022, 40:2491-507. 10.1200\/JCO.22.00687","journal-title":"J Clin Oncol"},{"key":"ref46","unstructured":"NCCN Guidelines. Cancer-related fatigue (Version 2.2026).. (2026). Accessed: April 10, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1424."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2024-109392","article-title":"Impact of exercise on health outcomes in people with cancer: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials","volume":"59","author":"Bai XL","year":"2025","unstructured":"Bai XL, Li Y, Feng ZF, et al.. Impact of exercise on health outcomes in people with cancer: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials. Br J Sports Med. 2025, 59:1010-20. 10.1136\/bjsports-2024-109392","journal-title":"Br J Sports Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09692-3","article-title":"The role of preoperative and postoperative exercise in enhancing quality of life following cystectomy for bladder cancer: a systematic review and meta-analysis","volume":"33","author":"G\u00fcney B","year":"2025","unstructured":"G\u00fcney B, Alomari O, Mokresh ME, et al.. The role of preoperative and postoperative exercise in enhancing quality of life following cystectomy for bladder cancer: a systematic review and meta-analysis. Support Care Cancer. 2025, 33:629. 10.1007\/s00520-025-09692-3","journal-title":"Support Care Cancer"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35608","article-title":"Prehabilitative\/rehabilitative exercise, nutrition, and psychological support for bladder cancer: a scoping review of randomized clinical trials","volume":"131","author":"Briggs LG","year":"2025","unstructured":"Briggs LG, Parke SC, Beck KL, et al.. Prehabilitative\/rehabilitative exercise, nutrition, and psychological support for bladder cancer: a scoping review of randomized clinical trials. Cancer. 2025, 131:e35608. 10.1002\/cncr.35608","journal-title":"Cancer"},{"key":"ref50","unstructured":"ClinicalTrials.gov. EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy (ENHANCE). (2022). Accessed: April 11, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05480735."},{"key":"ref51","unstructured":"ClinicalTrials.gov. A home-based prehabilitation exercise intervention for improving physical function in patients with bladder cancer and upper tract urothelial cancer, get moving trial. (2023). Accessed: April 11, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06040762."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-026-10316-7","article-title":"Efficacy of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis for randomized controlled trials","volume":"34","author":"Cai L","year":"2026","unstructured":"Cai L, Lin L, Xue J, et al.. Efficacy of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy: a systematic review and network meta-analysis for randomized controlled trials. Support Care Cancer. 2026, 34:174. 10.1007\/s00520-026-10316-7","journal-title":"Support Care Cancer"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad245","article-title":"Physical activity and checkpoint inhibition: association with toxicity and survival","volume":"116","author":"Verheijden RJ","year":"2024","unstructured":"Verheijden RJ, Caban\u00e9 Ballester A, Smit KC, et al.. Physical activity and checkpoint inhibition: association with toxicity and survival. J Natl Cancer Inst. 2024, 116:573-9. 10.1093\/jnci\/djad245","journal-title":"J Natl Cancer Inst"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-25-0682","article-title":"A retrospective cohort study of physical activity and survival in patients treated with immune checkpoint inhibitors","volume":"34","author":"Parker NH","year":"2025","unstructured":"Parker NH, Ramos JD, Tarhini AA, Schell MJ, Egan KM, Kanetsky PA. A retrospective cohort study of physical activity and survival in patients treated with immune checkpoint inhibitors. Cancer Epidemiol Biomarkers Prev. 2025, 34:2219-27. 10.1158\/1055-9965.EPI-25-0682","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1661503","article-title":"Efficacy and safety of traditional Chinese medicine (TCM) combined with immune checkpoint inhibitors (ICIs) for the treatment of cancer: a systematic review and meta-analysis","volume":"16","author":"Ke Y","year":"2025","unstructured":"Ke Y, Pan Y, Huang X, et al.. Efficacy and safety of traditional Chinese medicine (TCM) combined with immune checkpoint inhibitors (ICIs) for the treatment of cancer: a systematic review and meta-analysis. Front Pharmacol. 2025, 16:1661503. 10.3389\/fphar.2025.1661503","journal-title":"Front Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00584","article-title":"Association of hospitals' organizational characteristics and market factors offering integrative medicine services to adult patients with cancer","volume":"22","author":"Ajani S","year":"2026","unstructured":"Ajani S, Hearld KR, Niranjan SJ, Hall A, Lopez G, Borkowski N. Association of hospitals' organizational characteristics and market factors offering integrative medicine services to adult patients with cancer. JCO Oncol Pract. 2026, 22:639-47. 10.1200\/OP-25-00584","journal-title":"JCO Oncol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479722-threading-the-needle-in-bladder-cancer-a-narrative-review-of-the-emerging-role-of-integrative-oncology-in-treatment-related-adverse-events-in-the-era-of-immunotherapy-and-antibody-drug-conjugates","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:27:40Z","timestamp":1782142060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479722-threading-the-needle-in-bladder-cancer-a-narrative-review-of-the-emerging-role-of-integrative-oncology-in-treatment-related-adverse-events-in-the-era-of-immunotherapy-and-antibody-drug-conjugates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.111294","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}